B+
Bull case
20%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
PLX
Protalix BiotherapeuticsANYSE American / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Elfabrio growth, reaffirmed 2026 guidance, cash of $40.7 million, and continued PRX-115 enrollment provide a constructive operating setup. The long-term upside depends on commercial penetration and successful clinical execution.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Analyst revisions, options data, short interest, social sentiment, employee sentiment, and verified post-release price reaction are unavailable.
Momentum
98
Value
66
Sentiment
87
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.20 · Bull $4.50 · Bear $1.70Analysis 2026-09-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum98 · Δ7d -
Value66 · Δ7d -0.0
Sentiment87 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Analyst revisions, options data, short interest, social sentiment, employee sentiment, and verified post-release price reaction are unavailable.
- • PRX-115 clinical enrollment, safety, efficacy, and timing remain execution risks.
- • Revenue may remain lumpy because of partner shipments and inventory timing.
Catalyst clock
2026-12-31
PRX-115 Phase 2 enrollment progress
Lead driver: Sentiment · See AI snapshot
Momentum
98
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
66
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+3.5
Sentiment
87
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 98.3 / Value 65.9 / Sentiment 86.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-07. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.70
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$184.51M
Beta
-0.21
Shares Out
80.57M
P/E (TTM)
38.8
P/S (TTM)
2.33
P/FCF (TTM)
19.47
Rev YoY
+27.1%
EPS YoY
+2190.0%
Gross Margin
+69.2%
Op Margin
+28.9%
Net Debt
-$22.65M
Current Ratio
2.94
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data